A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents

NCT05169008 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

91

Enrollment

INDUSTRY

Sponsor class

Stopped Difficulty recruiting subjects, so the study was terminated.

Conditions

COVID-19

Interventions

BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
BIOLOGICAL: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)

Sponsor

CanSino Biologics Inc.

Collaborators

[object Object]